EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus

Alembic Pharmaceuticals appoints Manish Kejriwal as Independent Director

Vivity reaches 1 million milestone

Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

Venus Remedies receives Rs. 2.50 crore under PLI scheme

The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets

Bio-Techne partners with Nikon Instruments for innovative spatial biology services

Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024